Company Background & History

Cytogel Pharma LLC. is a clinical stage biopharmaceutical company dedicated to the discovery and development of safe and innovative treatments to finally resolve moderate to severe pain. Our scientists have worked diligently to build the Company's patent portfolio and have secured intellectual property protection for a number of compositions with attractive pharmaceutical properties that could substantially help patients.

Our lead compound, CYT-1010, is entering Phase 2 clinical development, following a successful Phase 1 study in humans. As the first member of a new class of drugs, the endomorphins, CYT-1010 is a breakthrough pain medicine which has demonstrated substantially reduced addiction potential and profoundly less risk of respiratory depression than has been experienced with traditional pain treatments. Offering an alternative in pain treatments could provide significant benefits across the country and in our communities.

Cytogel believes CYT-1010, when fully developed, will offer a transformational alternative drug treatment for pain that will ultimately provide greater relief and better outcomes for patients.